Latest news with #VIGL
Associated Press
22-05-2025
- Business
- Associated Press
Shareholder Alert: The Ademi Firm Investigates Whether Vigil Neuroscience Inc. Is Obtaining a Fair Price for Its Public Shareholders
MILWAUKEE--(BUSINESS WIRE)--May 22, 2025-- The Ademi Firm is investigating Vigil (Nasdaq: VIGL) for possible breaches of fiduciary duty and other violations of law in its transaction with Sanofi . Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, shareholders of Vigil will receive $8.00 per share of common stock in cash. Vigil shareholders will also receive a non-tradeable contingent value right (CVR) entitling the holder to potentially receive an additional $2.00 per share in cash payable following the first commercial sale of VG-3927 if achieved within a specific period. The total equity value of the transaction, including the potential CVR payment, represents approximately $600 million on a fully diluted basis. Vigil insiders will receive substantial benefits as part of change of control arrangements. The transaction agreement unreasonably limits competing transactions for Vigil by imposing a significant penalty if Vigil accepts a competing bid. We are investigating the conduct of the Vigil board of directors, and whether they are fulfilling their fiduciary duties to all shareholders. We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes. View source version on CONTACT: Ademi & Fruchter LLP Guri Ademi Toll Free: (866) 264-3995 Fax: (414) 482-8001 KEYWORD: UNITED STATES NORTH AMERICA WISCONSIN INDUSTRY KEYWORD: PROFESSIONAL SERVICES CLASS ACTION LAWSUIT SOURCE: Ademi & Fruchter LLP Copyright Business Wire 2025. PUB: 05/22/2025 08:14 AM/DISC: 05/22/2025 08:13 AM
Yahoo
01-03-2025
- Business
- Yahoo
Why Vigil Neuroscience, Inc. (VIGL) is Skyrocketing So Far in 2025
We recently published an article titled . In this article, we are going to take a look at where Vigil Neuroscience, Inc. (NASDAQ:VIGL) stands against the other biotech stocks. No matter the market environment, you'll always find entertainment in the biotech space. There will always be biotech stocks making huge swings in both directions and these stocks can make or break your portfolio in a very small amount of time due to the nature of how important clinical trial results are for these companies. The United Nations forecasts that the over-65 age group will grow by 150% from 800 million in 2024 to 2 billion by 2067. This "older, richer & sicker" population is expected to push global healthcare spending on medicines up 12% to $2.3 trillion by 2028. If you combine that with AI making breakthroughs in healthcare more frequent, you'll see many more biotech stocks starting to pop to the upside over the coming years. For this article, I screened the top-performing biotech stocks year-to-date. I will also mention the number of hedge fund investors in these stocks. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (). A medical technician observing a petri dish containing a monoclonal antibody sample. Number of Hedge Fund Holders In Q4 2024: 18 Vigil Neuroscience, Inc. (NASDAQ:VIGL) is a biotech company that makes treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. The stock is up significantly so far in 2025 in anticipation of upcoming clinical trial data readouts in the first half of 2025. It already reported positive Phase 1 clinical trial data for VG-3927 (small molecule TREM2 agonist) for Alzheimer's disease. Plus, a final analysis from the IGNITE Phase 2 clinical trial evaluating iluzanebart in adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) is planned for Q2 2025. In addition, it surged following announcements about promising progress in clinical trials for Alzheimer's and ALSP in January. The consensus price target of $19.75 implies 699.6% upside. Vigil Neuroscience, Inc. (NASDAQ:VIGL) is up 45% year-to-date. Overall VIGL ranks 15th on our list of the biotech stocks that are skyrocketing so far in 2025. While we acknowledge the potential of VIGL as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than VIGL but that trades at less than 5 times its earnings, check out our report about the . READ NEXT: Why These 15 E-Commerce Stocks Are Skyrocketing So Far In 2025 and Disclosure: None. This article is originally published at Insider Monkey.
